Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Gains from Sales and Divestitures (2017 - 2025)

Rocket Pharmaceuticals' Gains from Sales and Divestitures history spans 6 years, with the latest figure at $478289.0 for Q2 2025.

  • For Q2 2025, Gains from Sales and Divestitures changed N/A year-over-year to $478289.0; the TTM value through Jun 2025 reached $478289.0, changed N/A, while the annual FY2023 figure was $408119.0, 947.37% up from the prior year.
  • Gains from Sales and Divestitures for Q2 2025 was $478289.0 at Rocket Pharmaceuticals, up from $408119.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $478289.0 in Q2 2025 and bottomed at $38966.0 in Q4 2022.
  • The 3-year median for Gains from Sales and Divestitures is $156695.0 (2023), against an average of $227476.2.
  • The largest YoY upside for Gains from Sales and Divestitures was 947.37% in 2023 against a maximum downside of 947.37% in 2023.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $38966.0 in 2022, then soared by 947.37% to $408119.0 in 2023, then increased by 17.19% to $478289.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Gains from Sales and Divestitures are $478289.0 (Q2 2025), $408119.0 (Q4 2023), and $126093.0 (Q3 2023).